Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?

A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak of severe respiratory disease. This outbreak first detected in Wuhan, China in December 2019, has spread to other regions of China and to 25 other countries as of January, 2020. It has been known since the 2003 SARS...

Full description

Saved in:
Bibliographic Details
Published inClinical science (1979) Vol. 134; no. 5; pp. 543 - 545
Main Authors Batlle, Daniel, Wysocki, Jan, Satchell, Karla
Format Journal Article
LanguageEnglish
Published England 13.03.2020
Subjects
Animals
Betacoronavirus - pathogenicity
Cell Line
Coronavirus Infections - drug therapy
Haplorhini
Humans
Peptidyl-Dipeptidase A - physiology
Pneumonia, Viral - drug therapy
Recombinant Proteins - therapeutic use
SARS Virus - pathogenicity
Solubility
Virus Attachment
Virus Replication
angiotensin converting enzyme 2
Coronavirus
2019 Novel Coronavirus
Online AccessGet full text
ISSN0143-5221
1470-8736
1470-8736
DOI10.1042/CS20200163

Cover

More Information
Summary:A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak of severe respiratory disease. This outbreak first detected in Wuhan, China in December 2019, has spread to other regions of China and to 25 other countries as of January, 2020. It has been known since the 2003 SARS epidemic that the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. We thought that it is timely to explain the connection between the SARS-CoV, SARS-CoV-2, ACE2 and the rationale for soluble ACE2 as a potential therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
ISSN:0143-5221
1470-8736
1470-8736
DOI:10.1042/CS20200163